All News
Carpal Tunnel - Steroid injection vs. Night Splinting
A randomized trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSIor NS as the initial treatment of CTS.
https://t.co/dcE2P6RqoC https://t.co/pykkXs8qqi
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk of adverse outcomes in PsA pregnancies
More pre eclampsia
More Cesarian section
More preterms
By Dr.Chambers #RNL2023 @RheumNow https://t.co/LRiSSpv4Yj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Smoking *may* only ⬆️ risk of #RA if shared epitope present AND double positive
By @Janetbirdope #RNL2023 https://t.co/TG1hseVCsD
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
#RNL2023 Year in Review
@andreafava: urinary biomarkers in lupus nephritis
CD163, IL-16, CD206 decrease at 3 months.
Urinary biomarkers predict 1 year proteinuric response, esp in prolif LN.
Liquid biopsy as way to monitor instead of serial biopsies
@RheumNow https://t.co/baZt57Qjne
Eric Dein ericdeinmd ( View Tweet)
Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment
@RheumNow #RNL2023 https://t.co/kNDouZ4kCV
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
HCQ levels in SLE
>500 ng/mL = 19x higher adherence
>750 ng/mL 67% lower odds of adherence
Higher levels with CKD
I use HCQ levels in all patients for monitoring at each visit
@RheumNow https://t.co/6yCefQdPU0
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 Year in Review
COMPLETE-PsA: DMARDs for PsA!
LEF+MTX better than MTX alone, 78 total patients
PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO
More treatment discontinuations (10 vs 3) in combo group due to GI intolerance
@RheumNow https://t.co/3Al8PQmNli
Eric Dein ericdeinmd ( View Tweet)
PMR classification criteria by @anisha_dua @RheumNow #RNL2023
Bursal and biceps tenosynovitis gets one point in PMR classification criteria. https://t.co/Lj1X9mkgBz
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2023 Year in Review
Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA.
More targeted studies needed
@RheumNow https://t.co/Z3kbM0e9A0
Eric Dein ericdeinmd ( View Tweet)
Should we be measuring HCQ levels?
- note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels
- adjust dose for pts with renal impairment
@RheumNow #RNL2023 https://t.co/JvaRJKJRPv
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks
160 mg BKZ SQ q4w vs PBO
ACR50 43%, PBO 7%
PASI 1000: BKZ 58.5% vs PBO 4.5%
Safety: oral candidiasis: 2.6% BKZ vs PBO 0%
@RheumNow https://t.co/bW00Wg6Cnf
Eric Dein ericdeinmd ( View Tweet)
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49
Dr. Rachel Tate uptoTate ( View Tweet)
Could MTX every other week dosing be an option in patients with stable disease..?
#RNL2023 https://t.co/EZRdQnuXjy
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Urinary biomarkers in lupus nephritis
@RheumNow and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology!
#RNL2023 https://t.co/l1gQgFhviI
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Year in Review by Dr. Cush and Dr. Kavanaugh
Combo biologic therapy?
Phase II study from GI colleagues for UC
Guselkumab + golimumab
- no additional safety concerns
- improved clinical response
- extrapolate to rheumatology use?
#RNL2023 @RheumNow https://t.co/DirAovm1AX
Robert B Chao, MD doctorRBC ( View Tweet)
✅ RheumNow Live 2023
#RNL2023 @RheumNow
Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq
Laurent ARNAUD Lupusreference ( View Tweet)
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 @RheumNow
Safer?
No lab monitoring
And it works https://t.co/9Woen2q4hZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Beautiful summary of GPA management by Dr.Carol Langford #RNL2023 @RheumNow https://t.co/FCwKN9tovX
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
PMR lab studies by @anisha_dua @RheumNow #RNL2023
Majority of patients will have elevated inflammatory markers.
Rapid clinical response to low dose of steroid. https://t.co/AgdIJ5YbOu
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)